MiNK Therapeutics Files 8-K on Operations and Financials
Ticker: INKT · Form: 8-K · Filed: Aug 13, 2024 · CIK: 1840229
Sentiment: neutral
Topics: operations, financials, disclosure
TL;DR
MiNK Therapeutics dropped an 8-K detailing financials and operations. Check it out.
AI Summary
MiNK Therapeutics, Inc. filed an 8-K on August 13, 2024, reporting on its results of operations and financial condition. The filing also includes financial statements and exhibits. The company was formerly known as AgenTus Therapeutics, Inc., with a name change effective January 12, 2021.
Why It Matters
This 8-K filing provides investors with crucial updates on MiNK Therapeutics' financial health and operational status, impacting investment decisions.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of operational and financial information, not indicating any immediate adverse events.
Key Players & Entities
- MiNK Therapeutics, Inc. (company) — Registrant
- AgenTus Therapeutics, Inc. (company) — Former company name
- August 13, 2024 (date) — Date of earliest event reported
- January 12, 2021 (date) — Date of former company name change
FAQ
What is the primary purpose of this 8-K filing for MiNK Therapeutics, Inc.?
The primary purpose of this 8-K filing is to report on MiNK Therapeutics, Inc.'s results of operations and financial condition, and to include financial statements and exhibits.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on August 13, 2024.
What was MiNK Therapeutics, Inc. formerly known as?
MiNK Therapeutics, Inc. was formerly known as AgenTus Therapeutics, Inc.
On what date did the company's name change from AgenTus Therapeutics, Inc. to MiNK Therapeutics, Inc.?
The date of the name change from AgenTus Therapeutics, Inc. was January 12, 2021.
What is the principal executive office address for MiNK Therapeutics, Inc.?
The principal executive office address for MiNK Therapeutics, Inc. is 149 Fifth Avenue, Suite 500, New York, New York 10010.
Filing Stats: 515 words · 2 min read · ~2 pages · Grade level 10.1 · Accepted 2024-08-13 07:00:18
Key Financial Figures
- $0.00001 — ange on which registered Common Stock, $0.00001 par value per share INKT The NASDAQ Cap
Filing Documents
- f8k_081324.htm (8-K) — 15KB
- exh_991.htm (EX-99.1) — 52KB
- 0001171843-24-004721.txt ( ) — 268KB
- gnw-20190101.xsd (EX-101.SCH) — 3KB
- gnw-20190101_def.xml (EX-101.DEF) — 25KB
- gnw-20190101_lab.xml (EX-101.LAB) — 33KB
- gnw-20190101_pre.xml (EX-101.PRE) — 22KB
- f8k_081324_htm.xml (XML) — 3KB
02. Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition. On August 13, 2024, MiNK Therapeutics, Inc. announced its financial results for the quarter ended June 30, 2024. In connection with the announcement, the Company issued a press release, which is being furnished as Exhibit 99.1 to this current report on Form 8-K. The information set forth under Item 2.02 and in Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, except as expressly set forth by specific reference in such filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibit The following exhibit is furnished herewith: 99.1 Press Release dated August 13, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MiNK Therapeutics, Inc. Date: August 13, 2024 By: /s/ Christine M. Klaskin Christine M. Klaskin Principal Financial Officer